ArticleNaunyn-Schmiedeberg's archives of pharmacology2015
Restoration of CBX7 expression increases the susceptibility of human lung carcinoma cells to irinotecan treatment.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- CBX7 is involved in the progression of cervical cancer through the ITGβ3/TGFβ1/AKT pathway.Oncology letters · 2024Article
- Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells.Journal of ovarian research · 2023Article
- Adipose-derived exosomal miR-421 targets CBX7 and promotes metastatic potential in ovarian cancer cells.bioRxiv : the preprint server for biology · 2023Article
- Chromobox proteins in cancer: Multifaceted functions and strategies for modulation (Review).International journal of oncology · 2023Review
- Chromobox Homologue 7 Acts as a Tumor Suppressor in Both Lung Adenocarcinoma and Lung Squamous Cell Carcinoma via Inhibiting ERK/MAPK Signaling Pathway.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Diverse Chromobox Family Members: Potential Prognostic Biomarkers and Therapeutic Targets in Head and Neck Squamous Cell Carcinoma.International journal of general medicine · 2022Article
- Prognostic significance of HSF2BP in lung adenocarcinoma.Annals of translational medicine · 2021Article
- MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells.Cell cycle (Georgetown, Tex.) · 2021Article
- Comprehensive Analysis of the Expression and Prognosis Value of Chromobox Family Members in Clear Cell Renal Cell Carcinoma.Frontiers in oncology · 2021Article
- CBX7 is Dualistic in Cancer Progression Based on its Function and Molecular Interactions.Frontiers in genetics · 2021Review
- Key Common Genes in Obstructive Sleep Apnea and Lung Cancer are Associated with Prognosis of Lung Cancer Patients.International journal of general medicine · 2021Article
- Diverse CBX family members as potential prognostic biomarkers in non-small-cell lung cancer.FEBS open bio · 2020Article
- Novel immune subtypes of lung adenocarcinoma identified through bioinformatic analysis.FEBS open bio · 2020Article
- The Long Non-Coding RNACancers · 2020Article
- CBX7 Inhibits Cell Growth and Motility and Induces Apoptosis in Cervical Cancer Cells.Molecular therapy oncolytics · 2019Article
- Overexpression of CBX2 in breast cancer promotes tumor progression through the PI3K/AKT signaling pathway.American journal of translational research · 2019Article
- Prognostic values of distinct CBX family members in breast cancer.Oncotarget · 2017Article
- Critical role of HMGA proteins in cancer cell chemoresistance.Journal of molecular medicine (Berlin, Germany) · 2017Review
- miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene.BMC cancer · 2017Article
- Easy-to-use strategy for reference gene selection in quantitative real-time PCR experiments.Naunyn-Schmiedeberg's archives of pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the most common causes of cancer-related death worldwide in men and women, and, despite the recent remarkable scientific advances, drug treatment is still unsatisfactory. Polycomb protein chromobox homolog 7 (CBX7) is involved in several biological processes, including development and cancer progression, indeed the lack of CBX7 protein correlates with a highly malignant phenotype and a poor prognosis. However, its role in lung cancer still remains unknown. Since CBX7 is drastically downregulated in human lung carcinomas, we investigated whether restoration of CBX7 expression could affect growth property of lung cancer cells and modulate their sensitivity to treatment with irinotecan and etoposide, two chemoterapy drugs most commonly used in lung cancer therapy. Here, we demonstrate that restoration of CBX7 in two human lung carcinoma cell lines (A549 and H1299), in which this protein is not detectable, leads to a decreased proliferation (at least in part through a downregulation of phosphorylated ERK and phosphorylated p38) and an increased apoptotic cell death after drug exposure (at least in part through the downregulation of Bcl-2, phosphorylated Akt, and phosphorylated JNK). Taken together, these results suggest that the retention of CBX7 expression may play a role in the modulation of chemosensitivity of lung cancer patients to the treatment with irinotecan and etoposide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.